Characterization of a Novel Cullin5 Binding Domain in HIV-1 Vif

Journal of Molecular Biology

Volumn 373, Issue 3, 2007, Pages 541-550

  Xiao, Zuoxiang ^a   Xiong, Yong ^a,b   Zhang, Wenyan ^a   Tan, Lindi ^a   Ehrlich, Elana ^a   Guo, Deyin ^b   Yu, Xiao Fang ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b WUHAN UNIVERSITY   (China)

Author keywords

cullin; HIV; ubiquitin ligase; Vif; zinc

Indexed keywords

CULLIN; CYSTINE; CYTIDINE DEAMINASE; ELONGIN B; ELONGIN C; HISTONE; PROTEIN CULLIN5; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VIF PROTEIN; ZINC;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; UBIQUITINATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34748882327     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2007.07.029     Document Type: Article

References (61)

1. Bishop K.N., Holmes R.K., Sheehy A.M., Davidson N.O., Cho S.J., and Malim M.H. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14 (2004) 1392-1396
2. Bogerd H.P., Wiegand H.L., Doehle B.P., Lueders K.K., and Cullen B.R. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucl. Acids Res. 34 (2006) 89-95
3. Chen H., Lilley C.E., Yu Q., Lee D.V., Chou J., Narvaiza I., et al. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr. Biol. 16 (2006) 480-485
4. Chiu Y.L., Witkowska H.E., Hall S.C., Santiago M., Soros V.B., Esnault C., et al. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc. Natl Acad. Sci. USA 103 (2006) 15588-15593
5. Doehle B.P., Schafer A., and Cullen B.R. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339 (2005) 281-288
6. Esnault C., Millet J., Schwartz O., and Heidmann T. Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses. Nucl. Acids Res. 34 (2006) 1522-1531
7. Esnault C., Heidmann O., Delebecque F., Dewannieux M., Ribet D., Hance A.J., et al. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 433 (2005) 430-433
8. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., et al. DNA deamination mediates innate immunity to retroviral infection. Cell 113 (2003) 803-809
9. Hulme A.E., Bogerd H.P., Cullen B.R., and Moran J.V. Selective inhibition of Alu retrotransposition by APOBEC3G. Gene 390 (2007) 199-205
10. Kobayashi M., Takaori-Kondo A., Shindo K., Abudu A., Fukunaga K., and Uchiyama T. APOBEC3G targets specific virus species. J. Virol. 78 (2004) 8238-8244
11. Kremer M., Bittner A., and Schnierle B.S. Human APOBEC3G incorporation into murine leukemia virus particles. Virology 337 (2005) 175-182
12. Langlois M.A., Beale R.C., Conticello S.G., and Neuberger M.S. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucl. Acids Res. 33 (2005) 1913-1923
13. Lecossier D., Bouchonnet F., Clavel F., and Hance A.J. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300 (2003) 1112
14. Liddament M.T., Brown W.L., Schumacher A.J., and Harris R.S. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14 (2004) 1385-1391
15. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., and Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424 (2003) 99-103
16. Mariani R., Chen D., Schrofelbauer B., Navarro F., Konig R., Bollman B., et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114 (2003) 21-31
17. Muckenfuss H., Hamdorf M., Held U., Perkovic M., Lower J., Cichutek K., et al. APOBEC3 proteins inhibit human LINE-1 retrotransposition. J. Biol. Chem 281 (2006) 22161-22172
18. Noguchi C., Ishino H., Tsuge M., Fujimoto Y., Imamura M., Takahashi S., and Chayama K. G to A hypermutation of hepatitis B virus. Hepatology 41 (2005) 626-633
19. Rosler C., Kock J., Malim M.H., Blum H.E., and von Weizsacker F. Comment on "Inhibition of hepatitis B virus replication by APOBEC3G". Science 305 (2004) 1403
20. Schumacher A.J., Nissley D.V., and Harris R.S. APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc. Natl Acad. Sci. USA 102 (2005) 9854-9859
21. Stenglein M.D., and Harris R.S. APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J. Biol. Chem 281 (2006) 16837-16841
22. Suspene R., Guetard D., Henry M., Sommer P., Wain-Hobson S., and Vartanian J.P. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc. Natl Acad. Sci. USA 102 (2005) 8321-8326
23. Suspene R., Sommer P., Henry M., Ferris S., Guetard D., Pochet S., et al. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucl. Acids Res. 32 (2004) 2421-2429
24. Turelli P., Mangeat B., Jost S., Vianin S., and Trono D. Response to Comment on "Inhibition of Hepatitis B Virus Replication by APOBEC3G". Science 305 (2004) 1403b
25. Turelli P., Mangeat B., Jost S., Vianin S., and Trono D. Inhibition of hepatitis B virus replication by APOBEC3G. Science 303 (2004) 1829
26. Wiegand H.L., Doehle B.P., Bogerd H.P., and Cullen B.R. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23 (2004) 2451-2458
27. Yu Q., Chen D., Konig R., Mariani R., Unutmaz D., and Landau N.R. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J. Biol. Chem. 279 (2004) 53379-53386
28. Yu Q., Konig R., Pillai S., Chiles K., Kearney M., Palmer S., et al. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nature Struct. Mol. Biol. 11 (2004) 435-442
29. Zhang H., Yang B., Pomerantz R.J., Zhang C., Arunachalam S.C., and Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424 (2003) 94-98
30. Zheng Y.H., Irwin D., Kurosu T., Tokunaga K., Sata T., and Peterlin B.M. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78 (2004) 6073-6076
31. Guo F., Cen S., Niu M., Saadatmand J., and Kleiman L. Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J. Virol. 80 (2006) 11710-11722
32. Bishop K.N., Holmes R.K., and Malim M.H. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 80 (2006) 8450-8458
33. Mbisa J.L., Barr R., Thomas J.A., Vandegraaff N., Dorweiler I.J., Svarovskaia E.S., et al. HIV-1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 81 (2007) 7099-7110
34. Luo K., Wang T., Liu B., Tian C., Xiao Z., Kappes J., and Yu X.F. Cytidine deaminases APOBEC3G and APOBEC3F interact with HIV-1 integrase and inhibit proviral DNA formation. J. Virol. 81 (2007) 7238-7248
35. Kaiser S.M., and Emerman M. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J. Virol. 80 (2006) 875-882
36. Schrofelbauer B., Yu Q., Zeitlin S.G., and Landau N.R. Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J. Virol. 79 (2005) 10978-10987
37. Yang B., Chen K., Zhang C., Huang S., and Zhang H. Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J. Biol. Chem. 282 (2007) 11667-11675
38. Mehle A., Strack B., Ancuta P., Zhang C., McPike M., and Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279 (2003) 7792-7798
39. Shirakawa K., Takaori-Kondo A., Kobayashi M., Tomonaga M., Izumi T., Fukunaga K., et al. Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginC complex. Virology 344 (2006) 263-266
40. Yu X., Yu Y., Liu B., Luo K., Kong W., Mao P., and Yu X.F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302 (2003) 1056-1060
41. Mehle A., Goncalves J., Santa-Marta M., McPike M., and Gabuzda D. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 18 (2004) 2861-2866
42. Yu Y., Xiao Z., Ehrlich E.S., Yu X., and Yu X.F. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 18 (2004) 2867-2872
43. Luo K., Liu B., Xiao Z., Yu Y., Yu X., Gorelick R., and Yu X.F. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J. Virol. 78 (2004) 11841-11852
44. Luo K., Xiao Z., Ehrlich E., Yu Y., Liu B., Zheng S., and Yu X.F. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc. Natl Acad. Sci. USA 102 (2005) 11444-11449
45. Xiao Z., Ehrlich E., Yu Y., Luo K., Wang T., Tian C., and Yu X.F. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 349 (2006) 290-299
46. Mehle A., Thomas E.R., Rajendran K.S., and Gabuzda D. A Zinc-binding region in Vif Binds Cul5 and determines Cullin selection. J. Biol. Chem. 281 (2006) 17259-17265
47. Xiao Z., Ehrlich E., Luo K., Xiong Y., and Yu X.F. Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J. 21 (2007) 217-222
48. Dettenhofer M., and Yu X.F. Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions. J. Virol. 73 (1999) 1460-1467
49. Chackerian B., Long E.M., Luciw P.A., and Overbaugh J. Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J. Virol. 71 (1997) 3932-3939
50. Marin M., Rose K.M., Kozak S.L., and Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nature Med. 9 (2003) 1398-1403
51. Simon V., Zennou V., Murray D., Huang Y., Ho D.D., and Bieniasz P.D. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1 (2005) e6
52. Tian C., Yu X., Zhang W., Wang T., Xu R., and Yu X.F. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J. Virol. 80 (2006) 3112-3115
53. Schrofelbauer B., Senger T., Manning G., and Landau N.R. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J. Virol. 80 (2006) 5984-5991
54. Russell R.A., and Pathak V.K. Identification of two distinct HIV-1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 81 (2007) 8201-8210
55. Demene H., Dong C.Z., Ottmann M., Rouyez M. C., Jullian N., Morellet N., et al. 1H NMR structure and biological studies of the His23→Cys mutant nucleocapsid protein of HIV-1 indicate that the conformation of the first zinc finger is critical for virus infectivity. Biochemistry 33 (1994) 11707-11716
56. Ramboarina S., Druillennec S., Morellet N., Bouaziz S., and Roques B.P. Target specificity of human immunodeficiency virus type 1 NCp7 requires an intact conformation of its CCHC N-terminal zinc finger. J. Virol. 78 (2004) 6682-6687
57. Ramboarina S., Morellet N., Fournie-Zaluski M.C., and Roques B.P. Structural investigation on the requirement of CCHH zinc finger type in nucleocapsid protein of human immunodeficiency virus 1. Biochemistry 38 (1999) 9600-9607
58. Tanchou V., Decimo D., Pechoux C., Lener D., Rogemond V., Berthoux L., et al. Role of the N-terminal zinc finger of human immunodeficiency virus type 1 nucleocapsid protein in virus structure and replication. J. Virol. 72 (1998) 4442-4447
59. Knapska E., and Kaczmarek L. A gene for neuronal plasticity in the mammalian brain: Zif268/Egr-1/NGFI-A/Krox-24/TIS8/ZENK?. Prog. Neurobiol. 74 (2004) 183-211
60. Petersohn D., and Thiel G. Role of zinc-finger proteins Sp1 and zif268/egr-1 in transcriptional regulation of the human synaptobrevin II gene. Eur. J. Biochem. 239 (1996) 827-834
61. Green A., and Sarkar B. Alteration of zif268 zinc-finger motifs gives rise to non-native zinc-co-ordination sites but preserves wild-type DNA recognition. Biochem. J. 333 (1998) 85-90